tirzepatide phase 3 LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a trial of children and adolescents with type 2 diabetes Tirzepatide Shows Superior Weight Loss
Pay in 4 interest-free payments of $6.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20


01200-X/asset/1ec2c191-5a64-4856-842f-bfa65a8fabc6/main.assets/gr2.jpg)





















